Human Immunology News Volume 9.04 | Feb 2 2021

    0
    82



    HIN 9.04 | Feb 2 2021

    Human Immunology News by STEMCELL Technologies

    Vol. 9.04 – 2 February, 2021

    TOP STORY

    Opposing Immune and Genetic Mechanisms Shape Oncogenic Programs in Synovial Sarcoma

    Synovial sarcoma (SyS) is an aggressive neoplasm driven by the SS18–SSX fusion, and is characterized by low T cell infiltration. Scientists studied the cancer-immune interplay in SyS using an integrative approach that combined single-cell RNA sequencing, spatial profiling and genetic and pharmacological perturbations.
    [Nature Medicine]

    Abstract

    Start Fast. Finish Faster. Streamline your assays with purified human primary cells from STEMCELL Technologies. View products now.

    PUBLICATIONSRanked by the impact factor of the journal

    Stanniocalcin
    1 Is a Phagocytosis Checkpoint Driving Tumor Immune Resistance

    Investigators identified that expression of tumor stanniocalcin 1 correlated with immunotherapy efficacy and was negatively associated with patient survival across diverse cancer types.
    [Cancer Cell]

    AbstractGraphical Abstract

    Factors Associated with Outcomes after a Second CD19-Targeted CAR T-Cell Infusion for Refractory B-Cell Malignancies

    Researchers analyzed data from 44 patients with elapsed or refractory B-cell malignancies who received CD19-targeted chimeric antigen receptor-engineered on a Phase I/II trial.
    [Blood]

    Abstract

    A
    CD8+ NK Cell Transcriptomic Signature Associated with Clinical Outcome in Relapsing Remitting Multiple Sclerosis

    The authors applied hypothesis-generating network transcriptomics to CD8+ cells isolated from patients in relapsing/remitting multiple sclerosis, identifying a signature reflecting expansion of a subset of CD8+ natural killer (NK) cells associated with favorable outcome.
    [Nature Communications]

    Full Article

    Pretreatment
    Neutrophil-to-Lymphocyte Ratio and Mutational Burden As Biomarkers of Tumor Response to Immune Checkpoint Inhibitors

    In a retrospective cohort study of 1714 patients with 16 different cancer types treated with immune checkpoint inhibitors, scientists showed that higher neutrophil-to-lymphocyte ratio was significantly associated with poorer overall and progression-free survival.
    [Nature Communications]

    Full Article

    Transient
    Characteristics of Universal Cells on Human-Induced Pluripotent Stem Cells and Their Differentiated Cells Derived from Foetal Stem Cells with Mixed Donor Sources

    Investigators evaluated human leucocyte antigen (HLA)‐expressing class Ia and class II of their human‐induced pluripotent stem cells and their differentiated cells into embryoid bodies, cardiomyocytes and mesenchymal stem cells.
    [Cell Proliferation]

    Full Article

    Pro-Inflammatory Adiponectin in Pediatric-Onset Multiple Sclerosis

    The effect of recombinant adiponectin (APN) and APN-containing sera was assessed on functional responses of normal human peripheral blood myeloid and T cells and on human central nervous system-derived microglia.
    [Multiple Sclerosis Journal]

    Abstract

    Deferasirox
    Induces Cyclin D1 Degradation and Apoptosis in Mantle Cell Lymphoma in a Reactive Oxygen Species- and GSK3β-Dependent Mechanism

    Scientists demonstrated that the clinically approved iron chelator deferasirox exerted an anti‐tumoral effect in mantle cell lymphoma cell lines and patient cells.
    [British Journal of Haematology]

    Abstract

    Characterizing
    T Cell Subsets in the Nasal Mucosa of Children with Acute Respiratory Symptoms

    Investigators studied a convenience sample of 63 children presenting to a pediatric emergency department with respiratory symptoms. T cell subsets in the nasal mucosa were analyzed by flow cytometry.
    [Pediatric Research]

    Full Article


    Explore scientific events this February with the Science Events Calendar.

    REVIEWS

    Myeloid-Derived Suppressor Cells in the Era of Increasing Myeloid Cell Diversity

    The authors discuss new data on the major genomic and metabolic characteristics of myeloid-derived suppressor cells.
    [Nature Reviews Immunology]

    Full Article

    The BET Family in Immunity and Disease

    Scientists cover the accumulating data about the roles of the bromodomain and extraterminal domain (BET) family in innate immunity, and discuss the attractive prospect of manipulating the BET family as a new treatment for disease.
    [Signal Transduction and Targeted Therapy]

    Abstract

    HLA
    Class I Loss in Colorectal Cancer: Implications for Immune Escape and Immunotherapy

    Investigators summarize the prevalence and molecular mechanisms behind human leukocyte antigen class I (HLA-I) loss in colorectal cancer (CRC), and discuss HLA-I expression/loss in the context of the newly identified CRC molecular subtypes.
    [Cellular & Molecular Immunology]

    Abstract

    INDUSTRY AND POLICY NEWS

    Immudex Launches dCODE Dextramer® (RiO), a New Reagent Compatible with BD Rhapsody™ Single Cell Analysis System

    Immudex has announced the launch of dCODE Dextramer® reagents. These DNA barcoded MHC Dextramer® reagents are designed to be compatible with the BD Rhapsody™ system to be used for multiplexing, allowing the identification of many different T-cell specificities in the same sample.
    [Immudex (Life Science Newswire, Inc.)]

    Press Release

    FEATURED EVENT

    AACR: COVID-19 and Cancer

    February 3 – 5, 2021
    Virtual


    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral
    Fellow – Osteoarthritis

    Oklahoma Medical Research Foundation – Oklahoma City, Oklahoma, United States

    Postdoctoral Fellowship – Human Cancers

    Memorial Sloan Kettering Cancer Center – New York, New York, United States

    Postdoctoral Fellow Positions – Penn Epigenetics Institute

    University of Pennsylvania – Philadelphia, Pennsylvania, United States

    Professor or Associate Professor – Rheumatology

    The University of Utah School of Medicine – Salt Lake City, Utah, United States

    Research Scientist – Tumor Microenvironment

    Systimmune, Inc. – Redmond, Washington, United States

    > See All Jobs

    Submit an article, publication, job or event

    Brought to you by

    stemcell-logo-for newsletter-2

    Science News Human Immunology News
    Archives Contact Us

    Human Immunology News Twitter